Press Releases

Dec 16, 2019
BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia    read more...
Dec 13, 2019
BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019    read more...
Dec 08, 2019
BeiGene Announces Clinical Data on BRUKINSA™ (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting    read more...
Nov 26, 2019
BeiGene to Present at the 31st Annual Piper Jaffray Healthcare Conference    read more...
Nov 23, 2019
BeiGene Announces Clinical Data on Tislelizumab Presented at European Society for Medical Oncology (ESMO) Asia 2019 Congress    read more...
Nov 14, 2019
U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy    read more...
Nov 12, 2019
BeiGene Reports Third Quarter 2019 Financial Results    read more...
Nov 06, 2019
BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 61st American Society of Hematology Annual Meeting    read more...
Oct 31, 2019
BeiGene Announces Global Strategic Oncology Collaboration with Amgen    read more...
Sep 30, 2019
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019    read more...
Sep 26, 2019
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019    read more...
Sep 22, 2019
BeiGene Announces Clinical Results on Tislelizumab Presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)    read more...
Sep 11, 2019
BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)    read more...
Sep 08, 2019
BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update    read more...
Sep 03, 2019
BeiGene to Present at the Morgan Stanley 17th Annual Global Healthcare Conference    read more...
Aug 21, 2019
BeiGene Announces U.S. FDA Acceptance and Grant of Priority Review for its New Drug Application of Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma    read more...
Aug 08, 2019
BeiGene Reports Second Quarter 2019 Financial Results    read more...
Jul 07, 2019
Priority Review Granted to BeiGene’s Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma    read more...
Jun 28, 2019
BeiGene Granted Approval to Transition from the Biotech Chapter of the Hong Kong Stock Exchange to a General Listing    read more...
Jun 20, 2019
BeiGene Announces Phase 1b Clinical Results of Zanubrutinib in Combination with GAZYVA® (Obinutuzumab) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Follicular Lymphoma at the 15th International Conference on Malignant Lympho    read more...